Rédaction Africa Links 24 with Damian Garde
Published on 2024-01-31 14:36:32
In today’s biotech update, Novo Nordisk is increasing the availability of its obesity drug Wegovy for new U.S. patients as it reported a 31% increase in sales for 2023. Similarly, GSK and Novartis both reported their fourth quarter and 2023 earnings.
The controversy surrounding Biogen’s first approved medicine for Alzheimer’s disease, Aduhelm, has finally come to an end as the company decides to part ways with it and terminate an ongoing clinical trial. Vertex Pharmaceuticals’ novel pain drug showed promising results but is being debated over its potential to become a blockbuster.
23andMe, after a tough year, announced the FDA’s approval of the first clinical trial of a new drug called 23ME-01473. This marks the second medicine the company has derived from its DNA database to enter clinical trials. Pfizer, whose Covid-19 achievements turned into disappointment, surprisingly disclosed a profit in its latest earnings report.
Looking ahead, Pfizer will host an R&D event for its oncology pipeline and provide an update on its future in GLP-1 drugs later this year. Additionally, Boston Globe has listed the new hotspots for Boston-area biotech.
For more biotech updates in your inbox, sign up for our biotech newsletter. If you’ve made it to the end of this article, you might be interested in joining our secret list for an upcoming biotech newsletter. Just some food for thought.
